|
ISSN 1977-0987 |
||
|
Il-Ġurnal Uffiċjali tal-Unjoni Ewropea |
C 118 |
|
|
||
|
Edizzjoni bil-Malti |
Informazzjoni u Avviżi |
Volum 66 |
|
Werrej |
Paġna |
|
|
|
IV Informazzjoni |
|
|
|
INFORMAZZJONI MINN ISTITUZZJONIJIET, KORPI, UFFIĊĊJI U AĠENZIJI TAL-UNJONI EWROPEA |
|
|
|
Il-Kummissjoni Ewropea |
|
|
2023/C 118/01 |
||
|
2023/C 118/02 |
|
MT |
|
IV Informazzjoni
INFORMAZZJONI MINN ISTITUZZJONIJIET, KORPI, UFFIĊĊJI U AĠENZIJI TAL-UNJONI EWROPEA
Il-Kummissjoni Ewropea
|
31.3.2023 |
MT |
Il-Ġurnal Uffiċjali tal-Unjoni Ewropea |
C 118/1 |
Sommarju ta’ deċiżjonijiet tal-Unjoni Ewropea dwar l-awtorizzazzjonijiet għat-tqegħid fis-suq tal-prodotti mediċinali mill-1 ta’ Frar 2023 sat-28 ta’ Frar 2023
(Ippubblikat skont l-Artikolu 13 jew l-Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill (1) jew l-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill (2))
(2023/C 118/01)
— Ħruġ ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 13 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill): Aċċettat
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
INN (Denominazzjoni Internazzjonali Komuni) |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Forma farmaċewtika |
Kodiċi ATC (Kodiċi Anatomiku Terapewtiku Kimiku) |
Data ta' notifika |
||
|
15.2.2023 |
Dimethyl Fumarate Accord |
dimethyl fumarate |
|
EU/1/22/1711 |
Kapsula gastro-reżistenti, iebsa |
L04AX07 |
17.2.2023 |
||
|
20.2.2023 |
Hemgenix |
etranacogene dezaparvovec |
|
EU/1/22/1715 |
Konċentrat għal soluzzjoni għal infużjoni |
B06 |
23.2.2023 |
||
|
20.2.2023 |
IMJUDO |
tremelimumab |
|
EU/1/22/1713 |
Konċentrat għal soluzzjoni għal infużjoni |
L01FX20 |
23.2.2023 |
||
|
20.2.2023 |
Tremelimumab AstraZeneca |
tremelimumab |
|
EU/1/22/1712 |
Konċentrat għal soluzzjoni għal infużjoni |
L01FX20 |
21.2.2023 |
||
|
24.2.2023 |
Paxlovid |
Nirmatrelvir / ritonavir |
|
EU/1/22/1625 |
Pillola miksija b’rita |
J05AE30 |
27.2.2023 |
— Modifika ta' awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 13 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill): Aċċettat
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
3.2.2023 |
Ambirix |
|
EU/1/02/224 |
6.2.2023 |
||
|
3.2.2023 |
Bortezomib Hospira |
|
EU/1/16/1114 |
6.2.2023 |
||
|
3.2.2023 |
Copiktra |
|
EU/1/21/1542 |
17.2.2023 |
||
|
3.2.2023 |
Darunavir Mylan |
|
EU/1/16/1140 |
7.2.2023 |
||
|
3.2.2023 |
EVOTAZ |
|
EU/1/15/1025 |
6.2.2023 |
||
|
3.2.2023 |
Forxiga |
|
EU/1/12/795 |
6.2.2023 |
||
|
3.2.2023 |
Glivec |
|
EU/1/01/198 |
7.2.2023 |
||
|
3.2.2023 |
HALAVEN |
|
EU/1/11/678 |
8.2.2023 |
||
|
3.2.2023 |
Infanrix hexa |
|
EU/1/00/152 |
17.2.2023 |
||
|
3.2.2023 |
Invanz |
|
EU/1/02/216 |
9.2.2023 |
||
|
3.2.2023 |
KANJINTI |
|
EU/1/18/1281 |
6.2.2023 |
||
|
3.2.2023 |
Levetiracetam Accord |
|
EU/1/11/712 |
6.2.2023 |
||
|
3.2.2023 |
Nimvastid |
|
EU/1/09/525 |
14.2.2023 |
||
|
3.2.2023 |
NULIBRY |
|
EU/1/22/1684 |
9.2.2023 |
||
|
3.2.2023 |
Orencia |
|
EU/1/07/389 |
6.2.2023 |
||
|
3.2.2023 |
Pemetrexed Accord |
|
EU/1/15/1071 |
7.2.2023 |
||
|
3.2.2023 |
Quofenix |
|
EU/1/19/1393 |
8.2.2023 |
||
|
3.2.2023 |
Rasilez |
|
EU/1/07/405 |
13.2.2023 |
||
|
3.2.2023 |
Rixubis |
|
EU/1/14/970 |
9.2.2023 |
||
|
3.2.2023 |
SCENESSE |
|
EU/1/14/969 |
7.2.2023 |
||
|
3.2.2023 |
Sivextro |
|
EU/1/15/991 |
6.2.2023 |
||
|
3.2.2023 |
TRISENOX |
|
EU/1/02/204 |
7.2.2023 |
||
|
3.2.2023 |
Xagrid |
|
EU/1/04/295 |
6.2.2023 |
||
|
3.2.2023 |
Xigduo |
|
EU/1/13/900 |
6.2.2023 |
||
|
6.2.2023 |
Ebvallo |
|
EU/1/22/1700 |
7.2.2023 |
||
|
6.2.2023 |
Ebymect |
|
EU/1/15/1051 |
7.2.2023 |
||
|
6.2.2023 |
Hefiya |
|
EU/1/18/1287 |
7.2.2023 |
||
|
6.2.2023 |
Kerendia |
|
EU/1/21/1616 |
7.2.2023 |
||
|
6.2.2023 |
Tivicay |
|
EU/1/13/892 |
7.2.2023 |
||
|
6.2.2023 |
Xromi |
|
EU/1/19/1366 |
13.2.2023 |
||
|
9.2.2023 |
AMGLIDIA |
|
EU/1/18/1279 |
14.2.2023 |
||
|
9.2.2023 |
Brukinsa |
|
EU/1/21/1576 |
10.2.2023 |
||
|
9.2.2023 |
Tecentriq |
|
EU/1/17/1220 |
13.2.2023 |
||
|
15.2.2023 |
ASPAVELI |
|
EU/1/21/1595 |
17.2.2023 |
||
|
15.2.2023 |
Fulphila |
|
EU/1/18/1329 |
16.2.2023 |
||
|
15.2.2023 |
Hyrimoz |
|
EU/1/18/1286 |
20.2.2023 |
||
|
15.2.2023 |
JEMPERLI |
|
EU/1/21/1538 |
20.2.2023 |
||
|
15.2.2023 |
Lokelma |
|
EU/1/17/1173 |
16.2.2023 |
||
|
15.2.2023 |
Paxlovid |
|
EU/1/22/1625 |
16.2.2023 |
||
|
15.2.2023 |
Pemetrexed Krka |
|
EU/1/18/1283 |
20.2.2023 |
||
|
15.2.2023 |
Pregabalin Sandoz |
|
EU/1/15/1011 |
6.3.2023 |
||
|
15.2.2023 |
Semglee |
|
EU/1/18/1270 |
16.2.2023 |
||
|
15.2.2023 |
Trodelvy |
|
EU/1/21/1592 |
16.2.2023 |
||
|
15.2.2023 |
Vyndaqel |
|
EU/1/11/717 |
16.2.2023 |
||
|
15.2.2023 |
Zonegran |
|
EU/1/04/307 |
21.2.2023 |
||
|
20.2.2023 |
Aimovig |
|
EU/1/18/1293 |
22.2.2023 |
||
|
20.2.2023 |
Calquence |
|
EU/1/20/1479 |
21.2.2023 |
||
|
20.2.2023 |
Tractocile |
|
EU/1/99/124 |
3.3.2023 |
||
|
20.2.2023 |
Triumeq |
|
EU/1/14/940 |
21.2.2023 |
||
|
20.2.2023 |
Yuflyma |
|
EU/1/20/1513 |
21.2.2023 |
||
|
23.2.2023 |
Atosiban SUN |
|
EU/1/13/852 |
27.2.2023 |
||
|
23.2.2023 |
Gilenya |
|
EU/1/11/677 |
24.2.2023 |
||
|
23.2.2023 |
Ivabradine Accord |
|
EU/1/17/1190 |
24.2.2023 |
||
|
23.2.2023 |
Kinzalmono |
|
EU/1/98/091 |
24.2.2023 |
||
|
23.2.2023 |
Micardis |
|
EU/1/98/090 |
2.3.2023 |
||
|
23.2.2023 |
Nimenrix |
|
EU/1/12/767 |
24.2.2023 |
||
|
23.2.2023 |
Pemazyre |
|
EU/1/21/1535 |
24.2.2023 |
||
|
24.2.2023 |
Adcirca |
|
EU/1/08/476 |
27.2.2023 |
||
|
24.2.2023 |
Emselex |
|
EU/1/04/294 |
1.3.2023 |
||
|
24.2.2023 |
Febuxostat Mylan |
|
EU/1/17/1194 |
27.2.2023 |
||
|
24.2.2023 |
Pemazyre |
|
EU/1/21/1535 |
27.2.2023 |
||
|
24.2.2023 |
QINLOCK |
|
EU/1/21/1569 |
3.3.2023 |
||
|
24.2.2023 |
Rixathon |
|
EU/1/17/1185 |
27.2.2023 |
||
|
24.2.2023 |
Riximyo |
|
EU/1/17/1184 |
27.2.2023 |
||
|
24.2.2023 |
Ronapreve |
|
EU/1/21/1601 |
28.2.2023 |
||
|
24.2.2023 |
TUKYSA |
|
EU/1/20/1526 |
2.3.2023 |
||
|
24.2.2023 |
Wakix |
|
EU/1/15/1068 |
27.2.2023 |
||
|
27.2.2023 |
Abilify |
|
EU/1/04/276 |
7.3.2023 |
||
|
27.2.2023 |
Aflunov |
|
EU/1/10/658 |
28.2.2023 |
||
|
27.2.2023 |
Daptomycin Hospira |
|
EU/1/17/1175 |
28.2.2023 |
||
|
27.2.2023 |
Foclivia |
|
EU/1/09/577 |
28.2.2023 |
||
|
27.2.2023 |
NUBEQA |
|
EU/1/20/1432 |
28.2.2023 |
||
|
27.2.2023 |
Reblozyl |
|
EU/1/20/1452 |
28.2.2023 |
||
|
27.2.2023 |
Reblozyl |
|
EU/1/20/1452 |
28.2.2023 |
||
|
27.2.2023 |
Sprycel |
|
EU/1/06/363 |
28.2.2023 |
||
|
27.2.2023 |
Tecentriq |
|
EU/1/17/1220 |
28.2.2023 |
||
|
27.2.2023 |
Venclyxto |
|
EU/1/16/1138 |
28.2.2023 |
||
|
27.2.2023 |
Voriconazole Accord |
|
EU/1/13/835 |
28.2.2023 |
— Irtirar ta' awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 13 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill)
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
23.2.2023 |
Pregabalin Zentiva k.s |
|
EU/1/16/1166 |
24.2.2023 |
— Modifika ta' awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill; L-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill): Aċċettat
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
2.2.2023 |
Tulissin |
|
EU/2/20/252 |
6.2.2023 |
||
|
3.2.2023 |
Forceris |
|
EU/2/19/235 |
6.2.2023 |
||
|
3.2.2023 |
Locatim |
|
EU/2/99/011 |
9.2.2023 |
||
|
3.2.2023 |
Panacur AquaSol |
|
EU/2/11/135 |
7.2.2023 |
||
|
6.2.2023 |
Apoquel |
|
EU/2/13/154 |
7.2.2023 |
||
|
6.2.2023 |
CLYNAV |
|
EU/2/16/197 |
7.2.2023 |
||
|
6.2.2023 |
Procox |
|
EU/2/11/123 |
8.2.2023 |
||
|
6.2.2023 |
Procox |
|
EU/2/11/123 |
7.2.2023 |
||
|
6.2.2023 |
Versican Plus DHPPi/L4R |
|
EU/2/14/163 |
7.2.2023 |
||
|
9.2.2023 |
MiPet Easecto |
|
EU/2/17/220 |
14.2.2023 |
||
|
20.2.2023 |
Advocate |
|
EU/2/03/039 |
22.2.2023 |
||
|
20.2.2023 |
Bovela |
|
EU/2/14/176 |
22.2.2023 |
||
|
20.2.2023 |
GALLIPRANT |
|
EU/2/17/221 |
21.2.2023 |
||
|
20.2.2023 |
Suvaxyn Circo + MH RTU |
|
EU/2/15/190 |
23.2.2023 |
||
|
23.2.2023 |
Locatim |
|
EU/2/99/011 |
1.3.2023 |
Kull min jixtieq jikkonsulta r-rapport ta' evalwazzjoni pubblika dwar il-prodotti mediċinali kkonċernati u d-deċiżjonijiet marbuta magħhom għandu jikkuntattja lil:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |
|
31.3.2023 |
MT |
Il-Ġurnal Uffiċjali tal-Unjoni Ewropea |
C 118/9 |
Sommarju ta' deċiżjonijiet tal-Unjoni Ewropea dwar l-awtorizzazzjonijiet għat-tqegħid fis-suq tal-prodotti mediċinali mill-1 ta’ Frar 2023 sat-28 ta’ Frar 2023
(Deċiżjonijiet meħuda skont l-Artikolu 34 tad-Direttiva 2001/83/KE (1), l-Artikolu 38 tad-Direttiva 2001/82/KE (2) jew l-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill (3))
(2023/C 118/02)
— Ħruġ, manteniment jew modifika ta' awtorizzazzjoni għat-tqegħid fis-suq
|
Data tad-deċiżjoni |
Isem/Ismijiet tal-prodott mediċinali |
INN (Denominazzjoni Internazzjonali Komuni) |
Detentur(i) tal-awtorizzazzjoni għat-tqegħid fis-suq |
Stat Membru kkonċernat |
Data ta' notifika |
|
27.2.2023 |
Gelisia and associated names |
timolol maleate |
Ara l-Anness I |
Ara l-Anness I |
27.2.2023 |
|
15.2.2023 |
Rambis and associated names |
ramipril/bisoprolol fumarate |
Ara l-Anness II |
Ara l-Anness II |
16.2.2023 |
(1) ĠU L 311, 28.11.2001, p. 67.
ANNESS I
Lista ta’ prodotti mediċinali u preżentazzjonijiet
|
Stat Membru UE/ŻEE |
Applikant |
Isem Ivvintat |
Qawwa |
Għamla Farmaċewtika |
Rotta ta’ amministrazzjoni |
Kontenut (konċentrazzjoni) |
||||
|
Franza |
|
GENOPTOL |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
||||
|
Ġermanja |
|
Gelisia |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
||||
|
Italja |
|
GELISIA |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
||||
|
Olanda |
|
Gelisia |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
||||
|
Rumanija |
|
GELISIA |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
||||
|
Spanja |
|
TIMOLOL SIFI 1 MG/G GEL OFTALMICO |
1 mg/g |
Ġell għall-għajnejn |
Użu għall-għajnejn |
1 mg/g |
ANNESS II
Lista ta’ prodotti mediċinali u preżentazzjonijiet
|
Stat Membru UE/ŻEE |
Applikant |
Isem (Ivvintat) |
Qawwa |
Għamla farmaċewtika |
Mnejn jingħata |
||||
|
Ir-Repubblika Ċeka |
|
RALBIOR |
2,5 mg/1,25 mg (ramipril/bisoprolol fumarate) 2,5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/5 mg (ramipril/bisoprolol fumarate) 10 mg/5 mg (ramipril/bisoprolol fumarate) 10 mg/10 mg (ramipril/bisoprolol fumarate) |
Kapsula, iebsa |
Użu orali |
||||
|
Il-Polonja |
|
RAMBIS |
2,5 mg/1,25 mg (ramipril/bisoprolol fumarate) 2,5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/5 mg (ramipril/bisoprolol fumarate) 10 mg/ 5 mg (ramipril/bisoprolol fumarate) 10 mg/ 10 mg (ramipril/bisoprolol fumarate) |
Kapsula, iebsa |
Użu orali |
||||
|
Ir-Repubblika Slovakka |
|
RALBIOR 2,5 mg/1,25 mg tvrdé kapsuly; RALBIOR 5 mg/2,5 mg tvrdé kapsuly RALBIOR 5 mg/2,5 mg tvrdé kapsuly; RALBIOR 5 mg/5 mg tvrdé kapsuly; RALBIOR 10 mg/5 mg tvrdé kapsuly; RALBIOR 10 mg/10mg tvrdé kapsuly |
2,5 mg/1,25 mg (ramipril/bisoprolol fumarate) 2,5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/2,5 mg (ramipril/bisoprolol fumarate) 5 mg/5 mg (ramipril/bisoprolol fumarate) 1 0mg/ 5mg (ramipril/bisoprolol fumarate) 10 mg/ 10 mg (ramipril/bisoprolol fumarate) |
Kapsula, iebsa |
Użu orali |